# Evaluation of PK, PD, Efficacy, Safety, and Immunogenicity of IV Ravulizumab in Pediatric Participants With Generalized Myasthenia Gravis

Source: https://onco.cc/trials/nct05644561/  
OnCo record `nct05644561` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Ravulizumab in childhood cancers, run by Alexion Pharmaceuticals, Inc., active and no longer recruiting.

## Summary

Evaluation of PK, PD, Efficacy, Safety, and Immunogenicity of IV Ravulizumab in Pediatric Participants With Generalized Myasthenia Gravis is a phase 3 interventional study registered as NCT05644561 by Alexion Pharmaceuticals, Inc., with 12 participants enrolled, started 2023-06-24 and due to reach its primary completion in 2026-07-15. Interventions recorded: Ravulizumab.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05644561
- Phase: 3
- Setting: Phase 3, Open-label, Single-arm, Multicenter Study Evaluating Pharmacokinetics, Pharmacodynamics, Efficacy, Safety, and Immunogenicity of IV Ravulizumab in Pediatric Participants (6 to <18 Years) With Generalized Myasthenia Gravis (gMG)
- Sponsor: Alexion Pharmaceuticals, Inc.
- Enrolled: 12

## Sources

- ClinicalTrials.gov NCT05644561: https://clinicaltrials.gov/study/NCT05644561

## Connected records

- cancers: [Childhood cancers (all types)](https://onco.cc/cancers/childhood-cancers/)
- drugs: [Ravulizumab](https://onco.cc/drugs/ravulizumab/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)

---
JSON: https://onco.cc/api/v1/entities/nct05644561.json